Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials
- 31 March 2010
- journal article
- research article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 73 (3) , 220-227
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysisJNCI: Journal of the National Cancer Institute, 2006
- Fulvestrant (‘Faslodex’): Clinical experience from the Compassionate Use ProgrammeCancer Treatment Reviews, 2005
- Fulvestrant (‘Faslodex’) in pre-treated patients with advanced breast cancer: A single-centre experienceEuropean Journal of Cancer, 2005
- A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancerCancer Treatment Reviews, 2005
- Additive Antitumor Effect of Aromatase Inhibitor Letrozole and Antiestrogen Fulvestrant in a Postmenopausal Breast Cancer ModelCancer Research, 2005
- Fulvestrant versus anastrozole for the treatment of advanced breast carcinomaCancer, 2005
- Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized TrialJournal of Clinical Oncology, 2004
- Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal womenCancer, 2003
- To IPD or not to IPD?Evaluation & the Health Professions, 2002
- Uses and abuses of meta-analysisClinical Medicine, 2001